Swedish drugmaker Medivir (OMX: MVIR) has licensed exclusive rights to its hepatitis C virus (HCV) treatment MIV-802 to USA-based Trek Therapeutics, a private, clinical-stage public benefit corporation developing treatments for serious infections.
The deal will see Trek Therapeutics gain the rights to develop and commercialize the nucleotide polymerase inhibitor globally, excluding in China, Taiwan, Hong Kong and Macau.
Medivir is entitled to receive milestones based on successful clinical development and royalties capped at a mid-teens percentage upon commercialization of MIV-802 containing products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze